Apsen launches 'first psychobiotic' in Brazil

Apsen-launches-first-psychobiotic-in-Brazil.png
Image courtesy of Lallemand Health Solutions

São Paulo-based Apsen has partnered with Lallemand Health Solutions to launch a probiotic formulation for the brain-gut axis on the Brazilian market, with approved health claims by the Brazilian Health Authorities, ANVISA.

Probid and Probians, produced by Lallemand Health Solutions, were launched in September.

The products contain the documented probiotic combination of Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175.

The strain combination has been recognized by ANVISA for its safety and benefits in stressed healthy individuals, with approved claims including:

Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 may contribute to the reduction of feelings of anxiety in healthy individuals.

Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 contribute to the reduction of gastrointestinal complications such as abdominal pain and nausea/vomit brought on by light to moderate stress in healthy individuals.

“We are proud to be the first in Brazil to launch a specific probiotic formulation, based on two strains known for their proven effects on stress level and mood balance,” said Kleber Vargas, technical and business development vice-president at Apsen.

“Apsen invested in research to provide this evolution to the Brazilian market, with an innovative product with a full array of health benefits.”

Science

This specific probiotic formula is demonstrated to promote positive mood in stressful events and can help moderate physiological (Diop 2008) and psychological (Messaoudi 2010, 2011) responses to occasional stress, said Lallemand in a release.

Supported by five clinical studies and several pre-clinical studies have indicated the combination may exert its potential benefits on the gut-brain axis via eight mechanisms of action. The modes of action for this formula have been documented by nine mechanistic studies and five human studies on the brain-gut axis, said Lallemand.